Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238493 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101
A Phase 1 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05238493 is a Phase 1 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT05238493, a Phase 1 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is primarily designed to assess the safety and tolerability of single doses of VEL-101 when administered subcutaneously (via injection into an area under the skin) or intravenously (via infusion into a vein). As each new group of participants is enrolled into the study, the dose administered to that group may be higher than a previous dose shown to be safe in other participants. The study is also designed to determine blood levels of VEL-101 and some substances produced by the immune system following VEL-101 administration. This information can provide insight into how quickly VEL-101 is eliminated from the body and some if its effects on the body.
Interventions
- DRUG Placebo
- DRUG VEL-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238493
The ClinicalTrials.gov registry entry for NCT05238493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05238493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238493 about?
NCT05238493 is a clinical study titled "A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101". This study is primarily designed to assess the safety and tolerability of single doses of VEL-101 when administered subcutaneously (via injection into an area under the skin) or intravenously (via infusion into a vein). As each new group of participants is enrolled into the study, the dose administe...
What is the current status of trial NCT05238493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-04-26. Estimated completion is 2023-01-03.
What interventions are being tested in trial NCT05238493?
The interventions under investigation include: Placebo (DRUG), VEL-101 (DRUG).
Who is sponsoring clinical trial NCT05238493?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.